Type Size

    Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus

    The authors examined if receptor activator of NF-κB ligand (RANKL), a prototypic activator of NF-κB, contributes to the development of type 2 diabetes mellitus (T2DM) using both an epidemiological and experimental approach. In the prospective population-based study they found that a high serum concentration of soluble RANKL was a significant (P < 0.001) and independent predictor of T2DM manifestation. Furthermore, systemic or hepatic blockade of RANKL signaling in mouse models of T2DM caused a marked improvement of plasma glucose concentrations and glucose tolerance.

    Read Article

    Stefan Kiechl, Jürgen Wittmann, Andrea Giaccari, Michael Knoflach, Peter Willeit, Aline Bozec, et al

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details